MetaCap

Enveric Biosciences (ENVB) vs Theriva Biologics (TOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enveric Biosciences is the larger company by market cap ($6.0 million vs $5.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENVB-9.70%TOVX-48.72%
+4%-24%-51%
Oct 7, 20261 yearNov 20, 2026
ENVB-6.90%TOVX-44.70%
+7%-20%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENVB versus TOVX key metrics
MetricENVBTOVX
Share price$1.35$0.12
Market cap$6.04M$5.51M
1-day change-4.26%-6.25%
YTD return—-42.86%
1-year return—-45.45%
5-year return—-99.86%
P/E ratio (TTM)—0.10
EPS (TTM)$-13.01$1.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-23.74M
52-week high$13.25$0.49
52-week low$1.17$0.12
Distance from 52-week high-89.81%-75.51%
Analyst consensus—none
Avg. price target upside—+1983.33%
Average volume56.55K2.02M
Shares outstanding4.48M45.89M
Employees515
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enveric Biosciences

ENVB stock →

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ENVB vs TOVX FAQ

Which is bigger, Enveric Biosciences or Theriva Biologics?

Enveric Biosciences (ENVB) is larger, with a market capitalization of $6.04M compared with $5.51M for Theriva Biologics (TOVX).

Are Enveric Biosciences and Theriva Biologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons